PMID- 33162992
OWN - NLM
STAT- MEDLINE
DCOM- 20210614
LR  - 20231213
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 11
DP  - 2020
TI  - Clinical Significance of Serum Soluble TNF Receptor I/II Ratio for the 
      Differential Diagnosis of Tumor Necrosis Factor Receptor-Associated Periodic 
      Syndrome From Other Autoinflammatory Diseases.
PG  - 576152
LID - 10.3389/fimmu.2020.576152 [doi]
LID - 576152
AB  - Objectives: Genetic analysis of TNFRSF1A can confirm the diagnosis of tumor 
      necrosis factor receptor-associated periodic syndrome (TRAPS), but interpretation 
      of the pathogenesis of variants of unknown significance is sometimes required. 
      The aim of this study was to evaluate the clinical significance of serum soluble 
      tumor necrosis factor receptor type I (sTNFR-I)/II ratio to differentiate TRAPS 
      from other autoinflammatory diseases. Methods: Serum sTNFR-I and sTNFR-II levels 
      were measured using an enzyme-linked immunosorbent assay in patients with TRAPS 
      (n = 5), familial Mediterranean fever (FMF) (n = 14), systemic juvenile 
      idiopathic arthritis (s-JIA) (n = 90), and Kawasaki disease (KD) (n = 37) in the 
      active and inactive phase, along with healthy controls (HCs) (n = 18). Results: 
      In the active phase, the serum sTNFR-I/II ratio in patients with s-JIA, KD, and 
      FMF was significantly elevated compared with that in HCs, whereas it was not 
      elevated in patients with TRAPS. In the inactive phase, the serum sTNFR-I/II 
      ratio in patients with s-JIA and FMF was significantly higher compared with that 
      in HCs, and the ratio was lower in TRAPS patients than in patients with s-JIA and 
      FMF. Conclusions: Low serum sTNFR-I/II ratio in the active and inactive phase 
      might be useful for the differential diagnosis of TRAPS and other 
      autoinflammatory diseases.
CI  - Copyright (c) 2020 Yasumura, Shimizu, Toma, Yashiro, Yachie and Okada.
FAU - Yasumura, Junko
AU  - Yasumura J
AD  - Department of Pediatrics, Hiroshima University Graduate School of Biomedical and 
      Health Sciences, Hiroshima, Japan.
FAU - Shimizu, Masaki
AU  - Shimizu M
AD  - Department of Pediatrics, Graduate School of Medical Sciences, Kanazawa 
      University, Kanazawa, Japan.
FAU - Toma, Tomoko
AU  - Toma T
AD  - Department of Pediatrics, Graduate School of Medical Sciences, Kanazawa 
      University, Kanazawa, Japan.
FAU - Yashiro, Masato
AU  - Yashiro M
AD  - Department of Pediatrics, Okayama University Hospital, Okayama, Japan.
FAU - Yachie, Akihiro
AU  - Yachie A
AD  - Department of Pediatrics, Graduate School of Medical Sciences, Kanazawa 
      University, Kanazawa, Japan.
FAU - Okada, Satoshi
AU  - Okada S
AD  - Department of Pediatrics, Hiroshima University Graduate School of Biomedical and 
      Health Sciences, Hiroshima, Japan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20201014
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Biomarkers)
RN  - 0 (Receptors, Tumor Necrosis Factor, Type I)
RN  - 0 (Receptors, Tumor Necrosis Factor, Type II)
RN  - 0 (TNFRSF1A protein, human)
RN  - 0 (TNFRSF1B protein, human)
RN  - Periodic fever, familial, autosomal dominant
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Biomarkers/blood
MH  - Case-Control Studies
MH  - Child
MH  - Child, Preschool
MH  - Diagnosis, Differential
MH  - *Enzyme-Linked Immunosorbent Assay
MH  - Familial Mediterranean Fever/blood/*diagnosis/immunology
MH  - Female
MH  - Fever/blood/*diagnosis/immunology
MH  - Hereditary Autoinflammatory Diseases/blood/*diagnosis/immunology
MH  - Humans
MH  - Hyaline Fibromatosis Syndrome/blood/*diagnosis/immunology
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Middle Aged
MH  - Mucocutaneous Lymph Node Syndrome/blood/*diagnosis/immunology
MH  - Predictive Value of Tests
MH  - Receptors, Tumor Necrosis Factor, Type I/*blood
MH  - Receptors, Tumor Necrosis Factor, Type II/*blood
MH  - Young Adult
PMC - PMC7591697
OTO - NOTNLM
OT  - Kawasaki disease (KD)
OT  - familial Mediterranean fever
OT  - soluble tumor necrosis factor receptor
OT  - systemic juvenile idiopathic arthritis (sJIA)
OT  - tumor necrosis factor receptor associated periodic syndrome (TRAPS)
EDAT- 2020/11/10 06:00
MHDA- 2021/06/16 06:00
PMCR- 2020/01/01
CRDT- 2020/11/09 05:31
PHST- 2020/06/25 00:00 [received]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/11/09 05:31 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2020.576152 [doi]
PST - epublish
SO  - Front Immunol. 2020 Oct 14;11:576152. doi: 10.3389/fimmu.2020.576152. eCollection 
      2020.